Drug Trial Radar · NCT03386032
8-Week Atopic Dermatitis (AD) Treatment Study
Last checked: Nov 19, 2026Latest source record: Dec 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Nov 27, 2017
Primary completion
Aug 18, 2018
Study completion Aug 18, 2018
Sponsor
- Lead sponsor
- Procter and GambleIndustry
- Sponsor type
- Industry
- First posted
- Dec 29, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to investigate the clinical effectiveness of the Sponsor's experimental cream treatment on eczema as measured by visual grading of SCORAD (scoring of atopic dermatitis).
Conditions
- Atopic Dermatitis Eczema
Interventions
Investigational OTC CreamDrug
Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
0.05% DesonideDrug
Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions. Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions.
Placebo CreamOther
Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic DermatitisTime frame: Baseline to Week 8
- Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Severe Atopic DermatitisTime frame: Baseline to Week 8
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Wake Research, LLC
Raleigh, North Carolina
WR (Wake Research) ClinSearch
Chattanooga, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.